SG11201505862TA - Spiro-lactam nmda receptor modulators and uses thereof - Google Patents
Spiro-lactam nmda receptor modulators and uses thereofInfo
- Publication number
- SG11201505862TA SG11201505862TA SG11201505862TA SG11201505862TA SG11201505862TA SG 11201505862T A SG11201505862T A SG 11201505862TA SG 11201505862T A SG11201505862T A SG 11201505862TA SG 11201505862T A SG11201505862T A SG 11201505862TA SG 11201505862T A SG11201505862T A SG 11201505862TA
- Authority
- SG
- Singapore
- Prior art keywords
- spiro
- nmda receptor
- receptor modulators
- lactam nmda
- lactam
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361757942P | 2013-01-29 | 2013-01-29 | |
PCT/US2014/013639 WO2014120800A1 (en) | 2013-01-29 | 2014-01-29 | Spiro-lactam nmda receptor modulators and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201505862TA true SG11201505862TA (en) | 2015-08-28 |
Family
ID=50071824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201505862TA SG11201505862TA (en) | 2013-01-29 | 2014-01-29 | Spiro-lactam nmda receptor modulators and uses thereof |
Country Status (16)
Country | Link |
---|---|
US (2) | US9708335B2 (en) |
EP (1) | EP2951185B1 (en) |
JP (1) | JP2016506962A (en) |
KR (1) | KR20150110784A (en) |
CN (1) | CN105308049A (en) |
AU (1) | AU2014212501A1 (en) |
BR (1) | BR112015018094A2 (en) |
CA (1) | CA2899191A1 (en) |
EA (1) | EA201591405A1 (en) |
ES (1) | ES2618421T3 (en) |
IL (1) | IL240164A0 (en) |
MX (1) | MX2015009785A (en) |
PE (1) | PE20151436A1 (en) |
PH (1) | PH12015501598A1 (en) |
SG (1) | SG11201505862TA (en) |
WO (1) | WO2014120800A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102186883B (en) | 2008-09-18 | 2016-08-03 | 西北大学 | Nmda receptor regulator and its purposes |
KR20150110784A (en) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | Spiro-lactam nmda receptor modulators and uses thereof |
AU2014212485C1 (en) | 2013-01-29 | 2018-10-25 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
CN105229010A (en) * | 2013-01-29 | 2016-01-06 | 阿普廷伊克斯股份有限公司 | Spiral shell-lactan nmda receptor conditioning agent and uses thereof |
LT2951183T (en) | 2013-01-29 | 2019-05-27 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
JP2016506961A (en) | 2013-01-29 | 2016-03-07 | ノーレックス, インコーポレイテッドNaurex, Inc. | Spirolactam NMDA receptor modulator and use thereof |
AU2015271719A1 (en) | 2014-06-04 | 2016-12-01 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists |
CA2957898C (en) | 2014-09-15 | 2023-02-21 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
AU2016270677B2 (en) | 2015-06-01 | 2020-11-12 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists |
US20210198315A1 (en) * | 2016-02-01 | 2021-07-01 | Naurex, INC | Process for synthesis of peptide compounds |
CA3024606C (en) | 2016-05-19 | 2019-09-03 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
EP3490974B1 (en) * | 2016-08-01 | 2023-12-06 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
PE20190501A1 (en) * | 2016-08-01 | 2019-04-10 | Aptinyx Inc | NMDA ESPIRO-LACTAM MODULATORS AND METHODS OF USE OF THE SAME |
EA201990425A1 (en) * | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | SPIRO-LACTAM AND BIS-SPIRO-LACTAM MODULATORS OF THE NMDA RECEPTOR AND THEIR APPLICATION |
CA3031537A1 (en) * | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
IL286107B1 (en) | 2016-08-01 | 2024-05-01 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and usesthereof |
US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
WO2019152685A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and methods of using same |
WO2019152688A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
WO2019152696A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
BR112020015666A2 (en) * | 2018-01-31 | 2021-02-23 | Aptinyx Inc. | nmda receptor spiro-lactam modulators and their uses |
PE20210455A1 (en) * | 2018-01-31 | 2021-03-08 | Aptinyx Inc | SPIRO-LACTAMA NMDA RECEIVER MODULATORS AND USES OF THEM |
US11214563B2 (en) | 2019-06-14 | 2022-01-04 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators |
CN111018746A (en) * | 2019-12-16 | 2020-04-17 | 山东金城柯瑞化学有限公司 | Synthetic method of N-benzyloxycarbonyl-L-threonine amide as intermediate for main ring synthesis of aztreonam |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
CA2058975C (en) | 1990-10-30 | 2000-06-06 | Shuichi Kasai | Antiinflammatory gel preparation |
US5168103A (en) | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
FR2692268B1 (en) | 1992-06-15 | 1994-08-19 | Rhone Poulenc Rorer Sa | New polypeptides having NMDA receptor activity, nucleic acids encoding these polypeptides and uses. |
SE9301667D0 (en) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | NEW USE |
US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
DE69731747T2 (en) | 1996-06-07 | 2006-02-02 | Astrazeneca Ab | PEPTIDE DERIVATIVES |
WO1998005782A1 (en) | 1996-08-02 | 1998-02-12 | Zymogenetics, Inc. | Testis-specific insulin homolog polypeptides |
US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
JP3955345B2 (en) | 1996-09-27 | 2007-08-08 | サントリー株式会社 | New amino acid Daiji Harvein |
AU1585999A (en) | 1997-11-12 | 1999-05-31 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
US6274314B1 (en) | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
US6025471A (en) | 1998-06-03 | 2000-02-15 | Deghenghi; Romano | Diazaspiro, azepino and azabicyclo therapeutic peptides |
WO2000028090A2 (en) | 1998-11-12 | 2000-05-18 | Nyxis, Inc. | Diagnostic assay for cancer |
US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
AU1922301A (en) | 1999-11-17 | 2001-05-30 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
EP1255854A2 (en) | 2000-02-01 | 2002-11-13 | Agy Therapeutics, Inc. | Interaction of nmda receptor with protein tyrosine phosphatase |
AU2001268467A1 (en) | 2000-06-14 | 2001-12-24 | Nyxis Neurotherapies, Inc. | Identification of genes and compounds for treatment of cancer |
CA2413974A1 (en) | 2000-06-22 | 2001-12-27 | Nyxis Neurotherapies, Inc. | Neuroactive peptides for treatment of hypoxia and related conditions |
GB0018272D0 (en) | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
WO2002047535A2 (en) | 2000-12-14 | 2002-06-20 | Nyxis Neurotherapies, Inc. | High throughput assay to detect inhibitors of the map kinase pathway |
WO2002072005A2 (en) | 2001-03-07 | 2002-09-19 | University Of Utah Research Foundation | Linear y-carboxyglutamate rich conotoxins |
WO2002072609A2 (en) | 2001-03-12 | 2002-09-19 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
WO2003010540A1 (en) | 2001-07-25 | 2003-02-06 | Nyxis Neurotherapies, Inc. | Method of identifying nmda-related agent |
DK1519939T5 (en) | 2002-07-05 | 2011-01-24 | Targacept Inc | N-Aryl-diazaspirocyclic compounds and processes for their preparation and use |
US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
US7544478B2 (en) | 2003-08-08 | 2009-06-09 | The Burnham Institute | Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors |
US7662856B2 (en) | 2003-08-29 | 2010-02-16 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine |
GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
AU2005285292B2 (en) * | 2004-09-09 | 2011-03-10 | Merck Sharp & Dohme Corp. | Aryl spirolactam CGRP receptor antagonists |
US8003792B2 (en) * | 2004-09-13 | 2011-08-23 | Merck Sharp & Dohme Corp. | Bicyclic anilide spirolactam CGRP receptor antagonists |
WO2006034196A1 (en) | 2004-09-17 | 2006-03-30 | Lifelike Biomatic Inc. | Compositions for enhancing memory and methods therefor |
PL2030622T3 (en) | 2005-03-24 | 2011-07-29 | Univ Emory | Indication of dosage of progesterone in the treatment of a traumatic brain injury |
US7951912B2 (en) | 2005-08-26 | 2011-05-31 | Wisconsin Alumni Research Foundation | Poly-β-peptides from functionalized β-lactam monomers and antibacterial compositions containing same |
WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
CN101583612A (en) | 2006-09-15 | 2009-11-18 | 先灵公司 | Azetidinone derivatives and methods of use thereof |
JP2008188285A (en) | 2007-02-06 | 2008-08-21 | Bridgestone Corp | Back pad and vehicle seat |
CN101066945B (en) | 2007-05-25 | 2010-05-19 | 中国科学院上海有机化学研究所 | Process of synthesizing 3-substituted lactan compound |
CN101125817B (en) | 2007-08-03 | 2011-09-14 | 中国科学院上海有机化学研究所 | Method for synthesizing aldehyde substituted small ring amines compounds with high enantioselectivity and 3-substituted lactams compounds with optical activity |
WO2009039390A2 (en) | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
EP2257644B1 (en) | 2008-02-20 | 2015-06-24 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis of autism |
WO2010015545A1 (en) | 2008-08-07 | 2010-02-11 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
CN102186883B (en) * | 2008-09-18 | 2016-08-03 | 西北大学 | Nmda receptor regulator and its purposes |
WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
DE102009001460B4 (en) | 2009-03-11 | 2010-12-02 | Zf Friedrichshafen Ag | oilcontainer |
US20120178695A1 (en) | 2009-07-02 | 2012-07-12 | Joseph Moskal | Methods of treating neuropathic pain |
DK2485751T3 (en) | 2009-10-05 | 2014-08-18 | Univ Northwestern | GLYX-13 for use in a method of treating unaffected depression |
US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
AU2011215704B2 (en) | 2010-02-11 | 2015-07-23 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
KR101692275B1 (en) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | Secondary structure stabilized nmda receptor modulators and uses thereof |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
AU2012249397B2 (en) | 2011-04-27 | 2017-03-30 | Northwestern University | Methods of treating Alzheimer's disease, Huntington's disease, autism, or other disorders |
US9293690B2 (en) | 2011-06-27 | 2016-03-22 | Koninklijke Philips N.V. | Ultrasound transducer assembly and method of manufacturing the same |
AU2014212485C1 (en) | 2013-01-29 | 2018-10-25 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
JP2016506961A (en) | 2013-01-29 | 2016-03-07 | ノーレックス, インコーポレイテッドNaurex, Inc. | Spirolactam NMDA receptor modulator and use thereof |
KR20150110784A (en) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | Spiro-lactam nmda receptor modulators and uses thereof |
CN105229010A (en) | 2013-01-29 | 2016-01-06 | 阿普廷伊克斯股份有限公司 | Spiral shell-lactan nmda receptor conditioning agent and uses thereof |
LT2951183T (en) | 2013-01-29 | 2019-05-27 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
-
2014
- 2014-01-29 KR KR1020157023269A patent/KR20150110784A/en not_active Application Discontinuation
- 2014-01-29 MX MX2015009785A patent/MX2015009785A/en unknown
- 2014-01-29 ES ES14703750.1T patent/ES2618421T3/en active Active
- 2014-01-29 CA CA2899191A patent/CA2899191A1/en not_active Abandoned
- 2014-01-29 SG SG11201505862TA patent/SG11201505862TA/en unknown
- 2014-01-29 PE PE2015001571A patent/PE20151436A1/en not_active Application Discontinuation
- 2014-01-29 JP JP2015556106A patent/JP2016506962A/en not_active Withdrawn
- 2014-01-29 WO PCT/US2014/013639 patent/WO2014120800A1/en active Application Filing
- 2014-01-29 EA EA201591405A patent/EA201591405A1/en unknown
- 2014-01-29 CN CN201480018644.1A patent/CN105308049A/en active Pending
- 2014-01-29 AU AU2014212501A patent/AU2014212501A1/en not_active Abandoned
- 2014-01-29 EP EP14703750.1A patent/EP2951185B1/en active Active
- 2014-01-29 BR BR112015018094A patent/BR112015018094A2/en not_active IP Right Cessation
- 2014-01-29 US US14/764,426 patent/US9708335B2/en active Active
-
2015
- 2015-07-20 PH PH12015501598A patent/PH12015501598A1/en unknown
- 2015-07-27 IL IL240164A patent/IL240164A0/en unknown
-
2017
- 2017-06-16 US US15/625,163 patent/US10316041B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10316041B2 (en) | 2019-06-11 |
IL240164A0 (en) | 2015-09-24 |
ES2618421T3 (en) | 2017-06-21 |
EP2951185A1 (en) | 2015-12-09 |
US20150368254A1 (en) | 2015-12-24 |
US20180127430A1 (en) | 2018-05-10 |
KR20150110784A (en) | 2015-10-02 |
CA2899191A1 (en) | 2014-08-07 |
EP2951185B1 (en) | 2016-12-21 |
PE20151436A1 (en) | 2015-10-10 |
EA201591405A1 (en) | 2017-05-31 |
WO2014120800A1 (en) | 2014-08-07 |
BR112015018094A2 (en) | 2017-07-18 |
PH12015501598A1 (en) | 2015-10-19 |
AU2014212501A1 (en) | 2015-07-30 |
CN105308049A (en) | 2016-02-03 |
US9708335B2 (en) | 2017-07-18 |
MX2015009785A (en) | 2016-04-04 |
JP2016506962A (en) | 2016-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281240A (en) | Androgen receptor modulator and uses thereof | |
IL240166A0 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
HK1218417A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof - nmda | |
IL240164A0 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
HK1218418A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof - nmda | |
IL240165A0 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
HK1214532A1 (en) | Estrogen receptor modulator and uses thereof | |
HK1216500A1 (en) | Azetidine estrogen receptor modulators and uses thereof | |
IL245733A0 (en) | Aplnr modulators and uses thereof | |
HK1211923A1 (en) | Polycyclic estrogen receptor modulators and uses thereof | |
HK1245259A1 (en) | Pyridopyrimidinones and their use as nmda receptor modulators | |
IL245302A0 (en) | Nmda receptor modulators and prodrugs, salts, and uses thereof | |
GB201312727D0 (en) | Modulators | |
EP3013851A4 (en) | Bradykinin receptor modulators and use thereof | |
GB201304473D0 (en) | Modulators |